Hormonal regulation of feeding;Hormonalna regulacja przyjmowania pokarmu

Endokrynologia Polska

Volumn 60, Issue 4, 2009, Pages 296-301

  Kocełak, Piotr ^a   Zahorska Markiewicz, Barbara ^a   Olszanecka Glinianowicz, Magdalena ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Ghrelin; Obesity; Regulation of feeding

Indexed keywords

CHOLECYSTOKININ; CYTOKINE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; PEPTIDE YY [3-36]; GASTROINTESTINAL HORMONE;

ADIPOSE TISSUE; APPETITE; CALORIC INTAKE; CYTOKINE RELEASE; ENERGY BALANCE; FEEDING; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS; NEUROENDOCRINOLOGY; OBESITY; REVIEW; SIGNAL TRANSDUCTION; VAGUS NERVE; DIGESTION; EATING; FOOD INTAKE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

ADIPOSE TISSUE; APPETITE REGULATION; CHOLECYSTOKININ; CYTOKINES; DIGESTION; EATING; GASTROINTESTINAL HORMONES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOTHALAMUS; LEPTIN; OBESITY;

EID: 70350099119     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Zahorska-Markiewicz B. Otylość. Poradnik dla lekarzy. Archi-Plus, Kraków 2002: 7-17.
2. Anand BK., Brobeck JR. Hypothalamic control of food intake in rats and cats. Yale J Biol Med 1951; 24: 123-246.
3. Schwartz MW, Woods SC, Porte D Jr i wsp. Central nervous system control of food intake. Nature 2000; 404: 661-671.
4. Thorens B. Glucose sensing and the pathogenesis of obesity and type 2 diabetes. Int J Obes 2008; 32 (supl. 6): S62-S71.
5. Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 2004; 55: 137-154. (Pubitemid 38450982)
6. Mathis C, Moran T. H, Schwatz GJ. Load-sensitive rat gastric vagal afferents encode volume but not gastric nutrients. Am J Physiol 1998; 274: R280-R286.
7. Phillips RJ, Powley TL. Gastric volume rather than nutrient content inhibits food intake. Am J Physiol 1996; 271: R766-R769.
8. Schwartz GJ. The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 2000; 16: 866-873.
9. Considine RV, Sinha MK, Heiman ML i wsp. Serum immunoreactive-leptin concentrations in normal-weight and obese women. New Eng J Med 1996; 334: 292-295.
10. Baskin D, Breininger J, Schwartz M. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 1999; 48: 828-833. (Pubitemid 29153083)
11. Bjorbaek C, Elmquist JK, Michl P i wsp. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 1998; 139: 3485-3491.
12. Rohner-Jeanrenaud F. A neuroendocrine reappraisal of the dual-centre hypothesis: its implications for obesity and insulin resistance. Int. J. Obes. 1995; 19: 514-534.
13. Zarjevski N, Cusin I, Vettor R. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-1758. (Pubitemid 23295205)
14. Billington CJ, Briggs JE, Harker S i wsp. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol 1994; 266: R1765-R1770.
15. Mantzoros CS. The role of leptin in human obesity and disease: A review of the evidence. Ann Intern Med 1999; 130: 671-680. (Pubitemid 29196202)
16. Plant TM, Shahab M. Neuroendocrine mechanisms that delay and initiate puberty in higher primates. Physiol Behav 2002; 77: 717-722. (Pubitemid 36084426)
17. Schlicker E, Gross G, Fink K i wsp. Serotonin release in the brain cortex is inhibited by neuropeptide Y but not affected by ACTH1-24, angiotensin II, Bradykinin and delta-sleep-inducing peptide. Naunyn Schmiedebergs Arch Pharmacol 1991; 343: 117-122.
18. Rettori V, Milenkovic L, Riedel M i wsp. Physiological role of neuropeptide Y (NPY) in the control of anterior pituitary hormone release in the rat. Endocrinol Exp 1990; 24: 37-45.
19. Ren LM, Furukawa Y, Karasawa Y i wsp. Differential inhibition of neuropeptide Y on the chronotropic and inotropic response to sympathetic and parasympathetic stimulation in the isolated, perfused dog antrum. J Pharmacol Exp Ther 1991; 259: 38-43.
20. Korner J, Leibel R. To eat or not to eat -how the gut talks to the brain. New Eng J Med 2003; 349: 926-928. (Pubitemid 37064764)
21. Struwe M, Kaempfer SH, Geiger CJ i wsp. Effects of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993; 27: 827-831.
22. Di Marzo V, Goparaju SK, Wang L i wsp. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
23. Horvath T. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 2003; 112: 323-326. (Pubitemid 38063759)
24. Campfield L, Smith F, Gulsez Y i wsp. Mouse OB protein: evidence for a peripheral signal linking adiposity and central neural network. Science 1995; 269: 546-549.
25. Zhang Y, Proenca R, Maffei M i wsp. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
26. Chua SC, Chung WK, Wu-Peng XS i wsp. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB leptin receptor. Science 1996; 271: 994-996.
27. Bagdade JD, Bierman EL, Porte D Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967; 46: 1549-1557.
28. Kalra SP, Dube MG, Pu MG i wsp. Interacting appetiteregulating pathways in the hypothalamic regulation of body weight. Endocrine Rev 1999; 20: 68-100.
29. Salle A, Ryan M, Guilloteau G i wsp. Glucose controlrelated and non-glucose control-related effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients. Br J Nutr 2005; 94: 931-937.
30. Matson CA, Wiater MF, Kuijper JL i wsp. Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake. Peptides 1997; 18: 1275-1278.
31. Kojima M, Hosoda H, Date Y i wsp. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
32. Date Y, Kojima M, Hosoda H i wsp. Gherlin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141: 4255-4261.
33. Petersenn S. Structure and regulation of the growth hormone secretagogue receptor. Minevra Endocrinol 2002; 27: 243-256.
34. Nakazato M, Murakami N, Date Y i wsp. A role for gherlin in the central regulation of feeding. Nature 2001; 409: 194-198.
35. Murray CD, Booth CE, Bulmer DC i wsp. Ghrelin augments afferent response to distension in rat isolated jejunum. Neurogastroenterol Motil 2006; 18: 1112-1120.
36. Cummings DE, Purnell JQ, Frayo RS i wsp. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
37. Yoshihara F, Kojima M, Hosoda H i wsp. Ghrelin: a novel peptide for growth hormone release and feeding regulation. Curr Opin Clin Nutr Metab Care 2002; 5: 391-395.
38. Luger A. Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 2003; 52: 16-20. (Pubitemid 36042102)
39. Wren AM, Seal LJ, Cohen MA i wsp. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 2001; 86: 5992.
40. Otto B, Cuntz U, Fruehauf E i wsp. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145: 669-673.
41. Hansen TK, Dall R, Hosoda H i wsp. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 2002; 56: 203-206.
42. English PJ, Ghatei MA, Malik IA i wsp. Food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab. 2002; 87: 2984.
43. Adrian TE, Ferri GL, Bacarese-Hamilton AJ i wsp. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-1077.
44. Imamura M. Effects of surgical manipulation of the intestine on peptide YY and its physiology. Peptides 2002; 23: 403-407. (Pubitemid 34127979)
45. Schwartz MW, Morton GJ. Obesity: keeping hunger at bay. Nature 2002; 418: 595-597.
46. Stanley S, Wynne K, Bloom S. Gastrointestinal satiety signals. III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am J Physiol 2004; 286: G693-G697.
47. Wynne K, Stanley S, Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab 2004; 89: 3576-12582
48. Batterham RL, Cohen MA, Ellis SM i wsp. Inhibition of food intake in obese subjects by peptide YY3-36. N Eng J Med 2003; 349: 941-948. (Pubitemid 37064767)
49. Batterham RL, Cowley MA, Low MJ i wsp. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
50. Asakawa A, Inui A, Yuzuriha H i wsp. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003; 124: 1325-1336.
51. Katsuura G, Asakawa A, Inui A. Roles of pancreatic polypeptide in regulation of food intake. Peptides 2002; 23: 323-329. (Pubitemid 34127969)
52. Batterham RL, Le Roux CW, Cohen MA i wsp. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989-3992. (Pubitemid 37034556)
53. Kieffer TJ, McIntosch CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagons-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
54. Kreymann B, Williams G, Ghatei MA i wsp. Glucagon-like peptide 17-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
55. Verdich C, Toubro S, Buemann B i wsp. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001; 25: 1206-1214.
56. Dakin CL, Small CJ, Park AJ i wsp. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol 2002; 283: E1173-E1177.
57. Dakin CL, Small CJ, Batterham RL i wsp. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-2695.
58. Meeran K, O'Shea D, Edwards CM i wsp. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999; 140: 244-250.
59. Cohen MA, Eblis SM, Le-Roux C.i wsp. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696-4701.
60. Little J, Horowitz M, Feinle-Bisset C. Role of cholecystokinin in appetite control and body weight regulation. Obes Rev 2005; 6: 297-306. (Pubitemid 41578599)
61. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973; 84: 488-495.
62. Smith GP, Jerome C, Cushin BJ i wsp. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 1981; 213: 1036-1037.
63. Kissileff HR, Pi-Sunyer FX, Thornton J i wsp. Cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34: 154-160.
64. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983; 302: 703-706.
65. West DB, Frey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984; 246: R776-R787.